Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO

Conclusions: LFSPRO shows good performance in predicting TP53 mutations in individuals and families in varied situations. Impact: LFSPRO is more broadly applicable than the current clinical criteria and may improve clinical management for individuals and families with LFS. Cancer Epidemiol Biomarkers Prev; 26(6); 837–44. ©2017 AACR.

http://cebp.aacrjournals.org/cgi/content/short/26/6/837?rss=1

Source: Cancer Epidemiology Biomarkers and Prevention - May 31, 2017 Category: Cancer & Oncology Authors: Peng, G., Bojadzieva, J., Ballinger, M. L., Li, J., Blackford, A. L., Mai, P. L., Savage, S. A., Thomas, D. M., Strong, L. C., Wang, W. Tags: Research Articles Source Type: research